{"title":"法国里昂引入 Nirsevimab 后呼吸道合胞病毒相关住院病例流行病学的变化","authors":"Cécile Chauvel, Côme Horvat, Etienne Javouhey, Yves Gillet, Juliette Hassenboehler, Claire Nour Abou Chakra, Corinne Ragouilliaux, Franck Plaisant, Dominique Ploin, Marine Butin, Jean-Sebastien Casalegno, Marta C. Nunes","doi":"10.1111/irv.70054","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available from September 2023. We described RSV-associated LRTI hospitalisations during the 2023–2024 season among infants younger than six months born at the Hospices Civils de Lyon (HCL), and evaluated the effectiveness of Nirsevimab against RSV-LRTI hospitalisation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This observational study included infants born and hospitalised at the HCL during the 2023–2024 season, along with pre-COVID-19 and 2022–2023 seasons. Information on Nirsevimab immunisation status, clinical and perinatal variables were collected through routine care. Infants' characteristics and incidence rate of hospitalisation per 100 births during 2023–2024 were compared with the historical periods overall and by delay between birth and the onset of the RSV season. Nirsevimab effectiveness was computed by the screening method.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During the 2023–2024 season, 83 infants younger than six months were hospitalised with an RSV-associated LRTI. Compared with the historical periods (640 pre-COVID-19 and 123 in 2022–2023), these infants were older. Incidence rate for infants born during the period when immunisation was available were lower than the previous seasons; incidence rate ratios were 0.45 (95% confidence interval [CI]: 0.33; 0.62) in 2023–2024 compared with pre-COVID-19 period and 0.53 (95%CI: 0.36; 0.77) compared with 2022–2023 season. Nirsevimab effectiveness was 78.3% (95%CI: 55.9; 89.5) with a coverage of 79.3% in the two main HCL maternities.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>High Nirsevimab coverage and effectiveness were estimated in a real-world setting. A change in the age distribution of RSV-associated LRTI hospitalisations in 2023–2024 was noted compared with historical seasons.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 12","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70054","citationCount":"0","resultStr":"{\"title\":\"Changes in Respiratory Syncytial Virus-Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France\",\"authors\":\"Cécile Chauvel, Côme Horvat, Etienne Javouhey, Yves Gillet, Juliette Hassenboehler, Claire Nour Abou Chakra, Corinne Ragouilliaux, Franck Plaisant, Dominique Ploin, Marine Butin, Jean-Sebastien Casalegno, Marta C. Nunes\",\"doi\":\"10.1111/irv.70054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available from September 2023. We described RSV-associated LRTI hospitalisations during the 2023–2024 season among infants younger than six months born at the Hospices Civils de Lyon (HCL), and evaluated the effectiveness of Nirsevimab against RSV-LRTI hospitalisation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This observational study included infants born and hospitalised at the HCL during the 2023–2024 season, along with pre-COVID-19 and 2022–2023 seasons. Information on Nirsevimab immunisation status, clinical and perinatal variables were collected through routine care. Infants' characteristics and incidence rate of hospitalisation per 100 births during 2023–2024 were compared with the historical periods overall and by delay between birth and the onset of the RSV season. Nirsevimab effectiveness was computed by the screening method.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>During the 2023–2024 season, 83 infants younger than six months were hospitalised with an RSV-associated LRTI. Compared with the historical periods (640 pre-COVID-19 and 123 in 2022–2023), these infants were older. Incidence rate for infants born during the period when immunisation was available were lower than the previous seasons; incidence rate ratios were 0.45 (95% confidence interval [CI]: 0.33; 0.62) in 2023–2024 compared with pre-COVID-19 period and 0.53 (95%CI: 0.36; 0.77) compared with 2022–2023 season. Nirsevimab effectiveness was 78.3% (95%CI: 55.9; 89.5) with a coverage of 79.3% in the two main HCL maternities.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>High Nirsevimab coverage and effectiveness were estimated in a real-world setting. A change in the age distribution of RSV-associated LRTI hospitalisations in 2023–2024 was noted compared with historical seasons.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 12\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70054\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70054\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70054","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Changes in Respiratory Syncytial Virus-Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France
Background
Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available from September 2023. We described RSV-associated LRTI hospitalisations during the 2023–2024 season among infants younger than six months born at the Hospices Civils de Lyon (HCL), and evaluated the effectiveness of Nirsevimab against RSV-LRTI hospitalisation.
Methods
This observational study included infants born and hospitalised at the HCL during the 2023–2024 season, along with pre-COVID-19 and 2022–2023 seasons. Information on Nirsevimab immunisation status, clinical and perinatal variables were collected through routine care. Infants' characteristics and incidence rate of hospitalisation per 100 births during 2023–2024 were compared with the historical periods overall and by delay between birth and the onset of the RSV season. Nirsevimab effectiveness was computed by the screening method.
Results
During the 2023–2024 season, 83 infants younger than six months were hospitalised with an RSV-associated LRTI. Compared with the historical periods (640 pre-COVID-19 and 123 in 2022–2023), these infants were older. Incidence rate for infants born during the period when immunisation was available were lower than the previous seasons; incidence rate ratios were 0.45 (95% confidence interval [CI]: 0.33; 0.62) in 2023–2024 compared with pre-COVID-19 period and 0.53 (95%CI: 0.36; 0.77) compared with 2022–2023 season. Nirsevimab effectiveness was 78.3% (95%CI: 55.9; 89.5) with a coverage of 79.3% in the two main HCL maternities.
Conclusions
High Nirsevimab coverage and effectiveness were estimated in a real-world setting. A change in the age distribution of RSV-associated LRTI hospitalisations in 2023–2024 was noted compared with historical seasons.
期刊介绍：
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
